These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 11472706

  • 1. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia.
    McKenney JM, McCormick LS, Schaefer EJ, Black DM, Watkins ML.
    Am J Cardiol; 2001 Aug 01; 88(3):270-4. PubMed ID: 11472706
    [Abstract] [Full Text] [Related]

  • 2. Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy.
    Insull W, Toth PP, Superko HR, Thakkar RB, Krause S, Jiang P, Parreno RA, Padley RJ.
    Vasc Health Risk Manag; 2010 Nov 24; 6():1065-75. PubMed ID: 21191426
    [Abstract] [Full Text] [Related]

  • 3. [Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification].
    Li XP, Duan J, Zhao SP, Tan MY, Xu ZM, Zhang DQ.
    Zhonghua Yi Xue Za Zhi; 2006 Sep 12; 86(34):2399-403. PubMed ID: 17156651
    [Abstract] [Full Text] [Related]

  • 4. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
    Bays HE, Dujovne CA, McGovern ME, White TE, Kashyap ML, Hutcheson AG, Crouse JR, ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation.
    Am J Cardiol; 2003 Mar 15; 91(6):667-72. PubMed ID: 12633795
    [Abstract] [Full Text] [Related]

  • 5. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin.
    Bays HE, McGovern ME.
    Prev Cardiol; 2003 Mar 15; 6(4):179-88. PubMed ID: 14605511
    [Abstract] [Full Text] [Related]

  • 6. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.
    McKenney JM, McCormick LS, Weiss S, Koren M, Kafonek S, Black DM.
    Am J Med; 1998 Feb 15; 104(2):137-43. PubMed ID: 9528731
    [Abstract] [Full Text] [Related]

  • 7. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M, Egger P, Soudant C, Le Goff W, van Tol A, Dupuis R, Chapman MJ.
    Atherosclerosis; 2002 Aug 15; 163(2):287-96. PubMed ID: 12052475
    [Abstract] [Full Text] [Related]

  • 8. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.
    Pontrelli L, Parris W, Adeli K, Cheung RC.
    Metabolism; 2002 Mar 15; 51(3):334-42. PubMed ID: 11887170
    [Abstract] [Full Text] [Related]

  • 9. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
    Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ.
    Arterioscler Thromb Vasc Biol; 2000 Jan 15; 20(1):189-97. PubMed ID: 10634817
    [Abstract] [Full Text] [Related]

  • 10. Atorvastatin reduces remnant lipoproteins and small, dense low-density lipoproteins regardless of the baseline lipid pattern.
    O'Keefe JH, Captain BK, Jones PG, Harris WS.
    Prev Cardiol; 2004 Jan 15; 7(4):154-60. PubMed ID: 15539961
    [Abstract] [Full Text] [Related]

  • 11. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
    Krauss RM, Pinto CA, Liu Y, Johnson-Levonas AO, Dansky HM.
    J Clin Lipidol; 2015 Jan 15; 9(1):93-102. PubMed ID: 25670366
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S, Rajeev E, Tharakan JA, Titus T, Ajit Kumar VK, Sivasankaran S, Krishnamoorthy KM, Nair K.
    Indian Heart J; 2008 Jan 15; 60(3):215-22. PubMed ID: 19240310
    [Abstract] [Full Text] [Related]

  • 16. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.
    Soedamah-Muthu SS, Colhoun HM, Thomason MJ, Betteridge DJ, Durrington PN, Hitman GA, Fuller JH, Julier K, Mackness MI, Neil HA, CARDS Investigators.
    Atherosclerosis; 2003 Apr 15; 167(2):243-55. PubMed ID: 12818407
    [Abstract] [Full Text] [Related]

  • 17. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
    Diabetes Atorvastin Lipid Intervention (DALI) Study Group.
    Diabetes Care; 2001 Aug 15; 24(8):1335-41. PubMed ID: 11473066
    [Abstract] [Full Text] [Related]

  • 18. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
    Alaupovic P, Heinonen T, Shurzinske L, Black DM.
    Atherosclerosis; 1997 Aug 15; 133(1):123-33. PubMed ID: 9258416
    [Abstract] [Full Text] [Related]

  • 19. Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?
    Bays H, Conard S, Leiter LA, Bird S, Jensen E, Hanson ME, Shah A, Tershakovec AM.
    Lipids Health Dis; 2010 Nov 30; 9():136. PubMed ID: 21118495
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.